Press Releases

Regensburg Biotech Start-up Awarded Prize

A company, in its founding stages has again received recognition at the award presentation for the Business Plan Competition in northern Bavaria. Out of the 10 awarded companies, 5 come from the field of Life Sciences (biotechnology, medical technology) and demonstrate impressively that high quality biotech companies continue to flourish in spite of the national consolidation phase in northern Bavaria.

Biotech Hub in Eastern Bavaria

Eastern Bavaria and the city of Regensburg are gradually becoming highly lucrative locations for biotechnology interests. Two Regensburg companies, S-Refit AG and Lacuna AG were successful in the 2003 fiscal year.

Series production initiated: LabChips replace laboratory

Wilden AG based in Regensburg and november AG located in Erlangen combine their competences for the development and series production of microfluidic LabChips for near-patient nucleic acid, e.g. infectional diseases.

The Tumor Center in the BioPark Regensburg on a Path Towards Growth

The Tumor Center is another institution in the BioPark Regensburg, that is successfully expanding. The center is an equal partner, in a cooperative effort between the Clinic at the University of Regensburg, the area hospitals and established doctors from the Upper Palatinate (Oberpfalz). The center was recently awarded one of the prestigious “eEurope Awards for eHealth-2003” from the European Commission for Tele-Medicine.

NeuroProfile Founder Receives Award

The NeuroProfile Company has made it into the top five in the national Idée-Advancement Competition “Female Business Women Create Jobs” and makes it clear that even in the Oberpfalz women are successfully creating highly innovative employment positions.

Si4Health: A New Biotech-Tenant in BioPark

A new biotech company has moved into BioPark Regensburg. The company develops innovative materials for a new generation of Tissue Engineering, commonly used in the field of human medicine. Si4Health can already boast a worldwide turnover of 13.5 million euros in 2002.

The TK-Office as an important Interface for Genetic Technology

For several years, the Techniker Krankenkasse (TK-Technicians Health Care Company) has closely been following the developments of medical engineering in Bavaria. It is a particularly important topic for mandatory health care providers and therefore, biotech companies are important dialog partners for the insurance companies. The biotech companies are primarily involved in research to find new treatments, i.e. cancer, vaccinations, which are of great interest for health care providers.

Collaborative Agreement Between Amgen Inc. and Tularik Inc.

The California based biotech companies Amgen and Tularik have embarked on a close collaborative effort in the field of oncology (cancer treatment). Amgen has contributed 20 percent of its own capital to this partnership with Tularik and in a separate move has bought six million shares of Tularik’s common stocks. Tularik will in return receive 125 mill. US$ (110 mill. Euro) from Amgen.

Successful Round Financing for Profos AG

In spite of the current crisis in the venture capital arena, the Regensburg biotech company Profos AG has been able to convince the well-known international Danisco Venture Investment Corporation to collaborate. Through this the company will be substantially sustained and the basis for stronger growth and accelerated development will be secured.

Regensburg Expands its Business Contacts in the USA

Regensburg’s Mayor Hans Schaidinger has led another delegation to partner cities and partner companies in the USA. The participation of the city of Regensburg in the world’s largest biotech trade show, Bio2003 in Washington, D.C., successfully initiated further meetings in San Francisco, Ca., San Antonio, Tx., and Germantown, Md.